Mozobil, generically known as plerixafor, is a medication specifically designed to stimulate the mobilization of hematopoietic stem cells from the bone marrow into the bloodstream. This process is crucial for patients undergoing certain types of cancer treatments, such as autologous stem cell transplantation for conditions like multiple myeloma and non-Hodgkin's lymphoma. By blocking the CXCR4 receptor, Mozobil effectively increases the number of stem cells available for collection and subsequent transplantation. Administered via subcutaneous injection, it is often used in conjunction with granulocyte-colony stimulating factor (G-CSF) to enhance its stem cell mobilizing effects. Mozobil plays a vital role in improving the outcomes of stem cell transplants by ensuring a sufficient number of stem cells are collected for the procedure.